Becton, Dickinson and Co ((BDX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The clinical study titled A Randomized, Controlled Trial on the Safety, Efficacy, and Patient Reported Experience Comparing PureWick™ System With an Established Comparator Overnight in the Home Setting (PUREST) aims to evaluate the safety, efficacy, and user experience of the PureWick™ System for managing urine output overnight in a home setting. This study is significant as it seeks to improve quality of life for individuals with nighttime urinary incontinence.
Intervention/Treatment: The study tests two devices: the PureWick™ System, an experimental non-invasive urine management device, and the Hollister® Female Urinary Pouch, an active comparator. Both are designed to manage urine output for individuals with urinary incontinence.
Study Design: This interventional study follows a randomized, parallel assignment model with single masking for outcomes assessors. The primary purpose is supportive care, focusing on the comparative performance of the two devices in a real-world home setting.
Study Timeline: The study began on October 31, 2024, with its primary completion and last update recorded on July 22, 2025. These dates are crucial as they mark the study’s progression and the availability of updated information for stakeholders.
Market Implications: The completion of this study could influence Becton, Dickinson and Co’s stock performance by potentially enhancing investor confidence in the PureWick™ System’s market viability. As the healthcare industry continues to innovate in non-invasive solutions, this update may position BDX favorably against competitors.
The study is completed, and further details are available on the ClinicalTrials portal.